Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-Directed Therapy for Limited Stage DLBCL
NCT01359592Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2011
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Progression-free Survival at 5 years. Started Sep 2011; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01359592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01359592.